Introducing an Improved Tumor Fraction to Measure ctDNA Levels, & How to Incorporate ctDNA Monitoring to Gain Early Insights & Advance Clinical Research

Time: 9:00 am
day: Day One


  • Data on the value of tumor fraction for drug development and the need to move beyond median variant allele frequency (VAF) as a measure of ctDNA
  • Current use cases for ctDNA monitoring in early-stage disease and clinical research
  • How different approaches to ctDNA monitoring can meet the needs for those use cases, and the benefits of considering a portfolio approach